Mok, C. C. Towards new avenues in the management of lupus glomerulonephritis. Nat. Rev. Rheumatol. 12, 221–234 (2016).
Article CAS PubMed Google Scholar
Mok, C. C., Kwok, R. C. L. & Yip, P. S. F. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 65, 2154–2160 (2013).
Article CAS PubMed Google Scholar
Kandane-Rathnayake, R. et al. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. Lupus 28, 1669–1677 (2019).
Article CAS PubMed Google Scholar
Kharawala, S. et al. Health-related quality of life, fatigue and health utilities in lupus nephritis: a systematic literature review. Lupus https://doi.org/10.1177/09612033221100910 (2022).
Article PubMed PubMed Central Google Scholar
Jolly, M. et al. Disease-specific quality of life in patients with lupus nephritis. Lupus 27, 257–264 (2018).
Article CAS PubMed Google Scholar
Mok, C. C. & Tang, S. S. K. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am. J. Med. 117, 791–795 (2004).
Lewis, M. J. & Jawad, A. S. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology 56, i67–i77 (2017).
Parikh, S. V., Almaani, S., Brodsky, S. & Rovin, B. H. Update on lupus nephritis: core curriculum 2020. Am. J. Kidney Dis. 76, 265–281 (2020).
Tanaka, Y., O’Neill, S., Li, M., Tsai, I.-C. & Yang, Y.-W. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific Region. Arthritis Care Res. 74, 187–198 (2022).
Jakes, R. W. et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 64, 159–168 (2012).
Sexton, D. J. et al. ESRD from lupus nephritis in the United States, 1995–2010. Clin. J. Am. Soc. Nephrol. 10, 251–259 (2015).
Gómez-Puerta, J. A. et al. Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res. 67, 1453–1462 (2015).
Nee, R. et al. Survival disparity of African American versus Non-African American patients with ESRD due to SLE. Am. J. Kidney Dis. 66, 630–637 (2015).
Iwamoto, T. & Niewold, T. B. Genetics of human lupus nephritis. Clin. Immunol. 185, 32–39 (2017).
Article CAS PubMed Google Scholar
Freedman, B. I. et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66, 390–396 (2014).
Article CAS PubMed PubMed Central Google Scholar
Portalatin, G. M., Gebreselassie, S. K. & Bobart, S. A. Lupus nephritis — an update on disparities affecting African Americans. J. Natl Med. Assoc. 114, S34–S42 (2022).
Jordan, J., Thompson, N. J., Dunlop-Thomas, C., Lim, S. S. & Drenkard, C. Relationships among organ damage, social support, and depression in African American women with systemic lupus erythematosus. Lupus 28, 253–260 (2019).
Article CAS PubMed Google Scholar
Kumar, K. et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology 47, 690–697 (2008).
Article CAS PubMed Google Scholar
Hoi, A. Asian lupus in a multi-ethnic society: what can be learnt? Int. J. Rheum. Dis. 18, 113–116 (2015).
Rodríguez-Almaraz, E. et al. Something new about prognostic factors for lupus nephritis? A systematic review. Lupus 30, 2256–2267 (2021).
Moroni, G. et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann. Rheum. Dis. 77, 1318–1325 (2018).
Article CAS PubMed Google Scholar
Jorge, A. et al. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 71, 403–410 (2019).
Article PubMed PubMed Central Google Scholar
Tektonidou, M. G., Dasgupta, A. & Ward, M. M. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 68, 1432–1441 (2016).
Article PubMed PubMed Central Google Scholar
Anders, H.-J. et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrol. Dial. Transpl. https://doi.org/10.1093/ndt/gfab351 (2021).
Fanouriakis, A. et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713–723 (2020).
Article CAS PubMed Google Scholar
Mok, C. C. et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol. 3, e517–e531 (2021).
Rovin, B. H. et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases. Kidney Int. 100, 753–779 (2021).
Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797–808 (2012).
Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus Nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61–64 (2010).
Article CAS PubMed Google Scholar
Rathi, M. et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 89, 235–242 (2016).
Article CAS PubMed Google Scholar
Hsu, C.-Y. et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology 56, 620–628 (2017).
Mok, C. C., Lau, C. S. & Wong, R. W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831–837 (1998).
Article CAS PubMed Google Scholar
Mok, C. C. Mycophenolate mofetil for lupus nephritis: an update. Expert. Rev. Clin. Immunol. 11, 1353–1364 (2015).
Article CAS PubMed Google Scholar
Mok, C. C. et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann. Rheum. Dis. 79, 1070–1076 (2020).
Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18–26 (2015).
Mok, C. C. et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75, 30–36 (2016).
Austin, H. A., Illei, G. G., Braun, M. J. & Balow, J. E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901–911 (2009).
Article CAS PubMed PubMed Central Google Scholar
Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).
Article CAS PubMed PubMed Central Google Scholar
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Article CAS PubMed Google Scholar
Díaz-Lagares, C. et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun. Rev. 11, 357–364 (2012).
留言 (0)